F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid arthritis, metabolic dysfunction-associated steatohepatitis (MASH), giant cell arteritis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.

Laekna Therapeutics Shanghai Co. Ltd. patents describe new ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.

Apogee Pharmaceuticals Inc. has prepared fatty acid amide hydrolase (FAAH) inhibitors reported to be useful for the treatment of cancer, pain, inflammation, anxiety and mood disorders, cardiovascular disorders, autoimmune diseases and neurological disorders, among others.

The University of Minnesota has patented flavones having senolytic activity that are described as useful for the treatment of aging and Hutchinson-Gilford progeria syndrome.

Heterocyclic insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves’ ophthalmopathy) have been disclosed in a Horizon Therapeutics Ltd. patent.

Work at Exelixis Inc. has led to the development of antibody-drug conjugates (ADCs) comprising antibodies targeting interleukin-13 receptor subunit α2 (IL-13RA2, IL-13R-α2) covalently linked to a payload. They are described as potentially useful for the treatment of non-small-cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).

Brii Biosciences Inc. has identified substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives that are prodrugs of thyroid hormone receptor β (TH-β) agonists and reported to be useful for the treatment of multiple sclerosis.

Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) coupled to GTPase KRAS (G12D mutant)-targeting moiety through a linker.

TB Alliance has disclosed new ATP-dependent Clp protease ClpP1P2 complex (Mycobacterium tuberculosis) inhibitors reported to be useful for the treatment of tuberculosis.

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.